LFG
VRTX icon

Lockerman Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Lockerman Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-863
Closed -$338K – 122
2025
Q3 		$338K Hold
863
– – 0.43% 75
2025
Q2 		$384K Buy
863
+15
+2% +$6.91K 0.52% 60
2025
Q1 		$411K Sell
848
-1
-0.1% -$466 0.62% 48
2024
Q4 		$342K Hold
849
– – 0.58% 51
2024
Q3 		$395K Buy
849
+17
+2% +$8.17K 0.67% 48
2024
Q2 		$390K Buy
832
+298
+56% +$129K 0.71% 41
2024
Q1 		$223K Buy
+534
New +$226K 0.43% 91

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Lockerman Financial Group's VRTX Position: Q4 2025 in Review

Lockerman Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 863 shares — an estimated $338K sold.

Lockerman Financial Group first reported a position in VRTX in Q1 2024 and held it in 7 quarters. The position peaked at $411K in Q1 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Lockerman Financial Group reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Lockerman Financial Group sold 863 Vertex Pharmaceuticals shares in Q4 2025, an estimated $338K.
  • Lockerman Financial Group first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Lockerman Financial Group's Vertex Pharmaceuticals position peaked at $411K in Q1 2025.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Lockerman Financial Group's 13F filing for Q4 2025, filed 21 Jan 2026.